Literature DB >> 20298154

EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

Shailender Singh Kanwar1, Jyoti Nautiyal, Adhip P N Majumdar.   

Abstract

In the past 10 to 15 years, a considerable progress has been made in the treatment of gastrointestinal (GI) related malignancies, as number of agents expanded from only one in 1995 to seven in 2006. Current review describes the recent role of targeted therapies, specifically EGFR inhibitors in the treatment of GI cancers. Importance of dietary agents in the treatment and prevention of GI cancers is also reviewed.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20298154      PMCID： PMC3915939          DOI： 10.2174/138945010791170851

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN： 1389-4501            Impact factor:   3.465


  160 in total

Review 1.  The role of caspases in cell death and differentiation.

Authors:  Lisa Oliver; François M Vallette
Journal:  Drug Resist Updat       Date:  2005-06       Impact factor: 18.500

2.  Responsiveness to cetuximab without mutations in EGFR.

Authors:  Zenta Tsuchihashi; Shirin Khambata-Ford; Nasser Hanna; Pasi A Jänne
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

Review 3.  Cell proliferation in gastrointestinal mucosa.

Authors:  W M Wong; N A Wright
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

Review 4.  HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.

Authors:  G Giaccone
Journal:  Ann Oncol       Date:  2005-03-03       Impact factor: 32.976

5.  Curcumin synergizes with resveratrol to inhibit colon cancer.

Authors:  Adhip P N Majumdar; Sanjeev Banerjee; Jyoti Nautiyal; Bhaumik B Patel; Vaishali Patel; Jianhua Du; Yingjie Yu; Althea A Elliott; Edi Levi; Fazlul H Sarkar
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

6.  Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes.

Authors:  Matilde Todaro; Matilde D'Asaro; Nadia Caccamo; Flora Iovino; Maria Giovanna Francipane; Serena Meraviglia; Valentina Orlando; Carmela La Mendola; Gaspare Gulotta; Alfredo Salerno; Francesco Dieli; Giorgio Stassi
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 7.  Control of gut differentiation and intestinal-type gastric carcinogenesis.

Authors:  Yasuhito Yuasa
Journal:  Nat Rev Cancer       Date:  2003-08       Impact factor: 60.716

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 9.  Curcumin as "Curecumin": from kitchen to clinic.

Authors:  Ajay Goel; Ajaikumar B Kunnumakkara; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

10.  Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.

Authors:  S Uchino; H Tsuda; K Maruyama; T Kinoshita; M Sasako; T Saito; M Kobayashi; S Hirohashi
Journal:  Cancer       Date:  1993-12-01       Impact factor: 6.860
View more
  4 in total

1.  Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy.

Authors:  Ning Zhao; Bingbing Ding; Ying Zhang; Jessica L Klockow; Ken Lau; Frederick T Chin; Zhen Cheng; Hongguang Liu
Journal:  J Control Release       Date:  2020-05-23       Impact factor: 9.776

Review 2.  Role of ErbB1 in the Underlying Mechanism of Lapatinib-Induced Diarrhoea: A Review.

Authors:  Raja Nur Firzanah Syaza Raja Sharin; Jesmine Khan; Mohamad Johari Ibahim; Mudiana Muhamad; Joanne Bowen; Wan Nor I'zzah Wan Mohamad Zain
Journal:  Biomed Res Int       Date:  2022-06-28       Impact factor: 3.246

3.  Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells.

Authors:  Jyoti Nautiyal; Shailender S Kanwar; Yingjie Yu; Adhip Pn Majumdar
Journal:  J Mol Signal       Date:  2011-07-20

4.  Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.

Authors:  Tung-Cheng Chang; Yu-Tang Chin; André Wendindondé Nana; Shwu-Huey Wang; Yu-Min Liao; Yi-Ru Chen; Ya-Jung Shih; Chun A Changou; Yu-Chen Sh Yang; Kuan Wang; Jacqueline Whang-Peng; Liang-Shun Wang; Steven C Stain; Ai Shih; Hung-Yun Lin; Chih-Hsiung Wu; Paul J Davis
Journal:  Horm Cancer       Date:  2018-09-05       Impact factor: 3.869
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.